A 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural network that combined structural MRI regional features with clinical variables to classify cognitively normal controls, mild cognitive impairment, and Alzheimer’s disease.1 The result is useful, but the clinical-feature ablation dropped accuracy to 68.35%, so the model should be read as multimodal decision-support research, …
A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. The number is large for ALS, but the long-term comparison is historical and modeled rather than randomized placebo follow-up.1 Research Highlights 42.3% reached 5 years from onset: Ludolph et al. …
A 2026 single-cell and spatial-transcriptomics study of 21,156 brain immune cells found that late amyloid disease shifted interferon-driven neuroinflammation from microglia toward plaque-associated CD8 T cells, with T-cell frequency strongly tracking total amyloid deposits (Spearman rho = 0.844, p < 0.0001).1 The result does not turn Alzheimer’s disease into an autoimmune disease, but it makes …
A 2026 pilot randomized trial in 16 frail adults with multiple sclerosis found that 6 weeks of supervised multimodal exercise was feasible: retention was 87.5%, adherence was 97.2%, no adverse events were recorded, and fatigue and quality-of-life scores moved more than they did with waitlist control.1 Research Highlights Feasibility cleared the prespecified bar: 14 of …
A 2026 medRxiv preprint found that a training-free speech biomarker tracked dysarthria severity across 890 speakers, 10 corpora, and 5 full-pipeline languages, with all 5 consonant d-prime features showing random-effects correlations with clinical severity (rho = −0.50 to −0.56; all p < 2e−4). Research Highlights Speech-severity signal was broad: Muller et al. evaluated 890 speakers …
A 2026 medRxiv case-control study found that serum myelin oligodendrocyte glycoprotein was 20.5 pg/ml higher in multiple sclerosis than in healthy donors and 15.3 pg/ml higher during relapse than remission, making it a plausible blood marker of demyelination rather than a replacement for neurofilament light chain. Research Highlights MOG was higher in MS: serum myelin …
A 2026 cerebrospinal-fluid proteomics preprint involving 87 amyotrophic lateral sclerosis (ALS) patients, 89 healthy controls, and 61 neurological controls reported 399 ALS candidate proteins, complement markers that tracked disease stage, and a 5-protein panel that classified ALS vs. healthy controls with ROC AUC 0.95 after the best-known neurodegeneration markers were removed.1 Research Highlights CSF proteomics …